David Lorance, MD
Neurology · Bozeman, MTNPI 1316366495
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 28.9% of the total. 2025 is the largest year on record at $426, more than ten times the $22 reported in 2022. That places this record below the midpoint for neurology clinicians in MT, where the typical reported total is $1,082.
Across 25 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$155
- AbbVie$113
- Pfizer$87
- AstraZeneca$44
- Bristol Myers Squibb$31
- CSL Behring$30
- plus $74 from 4 others
What the payments were for
- Food & beverage$534100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 6 | $155 |
| AbbVie | 5 | $113 |
| Pfizer | 5 | $87 |
| AstraZeneca | 2 | $44 |
| Bristol Myers Squibb | 2 | $31 |
| CSL Behring | 1 | $30 |
| Argenx US, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Novartis | 1 | $16 |
How this compares
$534 in reported general payments places this provider in the 45th percentile of 48 neurology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 27 | $386,395 |
| GlatopaGlatiramer Acetate | 11 | $29,568 |
| Emgality PenGalcanezumab-Gnlm | 16 | $11,114 |
| Riluzole | 19 | $5,368 |
| Lacosamide | 13 | $4,074 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 85 | $2,236 |
| Pyridostigmine Bromide | 19 | $2,113 |
| Pregabalin | 34 | $1,604 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 13 | $1,018 |
| Lamotrigine | 31 | $809 |
| Gabapentin | 43 | $808 |
| Levetiracetam | 29 | $478 |
| Zonisamide | 11 | $345 |
| Prednisone | 30 | $253 |
| Donepezil Hcl | 12 | $159 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bozeman
- Emily PharrBozeman$14K
- Mario PizziniBozeman$3K
- Matthew BainBozeman$200
- James RaglandBozeman$194
- Richard PopwellBozeman$62
- Joshua KnappenbergerBozeman$51
- Ann CollierBillings$164K
- Dennis DietrichGreat Falls$140K
- Nicole ClarkHelena$85K
- Kristian FrenchBillings$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.